NCM
MAZE

Nantahala Capital Management’s Maze Therapeutics MAZE Stock Holding History

Nantahala Capital Management’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-93,351
Closed -$2.42M – 173
2025
Q3 		$2.42M Buy
+93,351
New +$1.58M 0.08% 130

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Nantahala Capital Management's MAZE Position: Q4 2025 in Review

Nantahala Capital Management sold out of Maze Therapeutics (MAZE) in Q4 2025, closing a stake of 93,351 shares — an estimated $2.42M sold.

Nantahala Capital Management first reported a position in MAZE in Q3 2025 and held it in 1 quarter. The position peaked at $2.42M in Q3 2025. 143 funds tracked by Wall St. Rank hold MAZE as of Q4 2025.

  • Nantahala Capital Management reported no remaining Maze Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Nantahala Capital Management sold 93,351 Maze Therapeutics shares in Q4 2025, an estimated $2.42M.
  • Nantahala Capital Management first reported a position in Maze Therapeutics in Q3 2025 and held it in 1 quarter.
  • Nantahala Capital Management's Maze Therapeutics position peaked at $2.42M in Q3 2025.
  • 143 funds tracked by Wall St. Rank held Maze Therapeutics as of Q4 2025.

Based on Nantahala Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.